Lower mortality risk associated with remdesivir + dexamethasone versus dexamethasone alone for the treatment of patients hospitalized for COVID-19.

Essy MozaffariAastha ChandakRobert L GottliebChidinma Chima-MeltonMark BerryThomas OppeltJason F OkuliczAlpesh N AminTobias WeltePaul E SaxAndre C Kalil

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)

Remdesivir+dexamethasone was associated with a significant reduction in 14- and 28-day mortality compared to dexamethasone alone in patients hospitalized for COVID-19 across all levels of baseline respiratory support, including IMV/ECMO. However, the use of remdesivir+dexamethasone still has low clinical practice uptake. In addition, these data suggest a need to update the existing guidelines.

Keyphrases

high dose
low dose
coronavirus disease
clinical practice
sars cov
end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
acute respiratory distress syndrome
extracorporeal membrane oxygenation
risk factors
intensive care unit
patient reported outcomes
big data
respiratory tract